Dyspepsia: management guidelines for the millennium
- Correspondence to:
Professor N J Talley, Department of Medicine, University of Sydney, Nepean Hospital, Penrith 2751, NSW, Australia;
The annual prevalence of dyspepsia in Western countries is approximately 25%, and the condition accounts for 2–5% of all primary care consultations, yet optimal management remains a subject of considerable debate. Some of the outstanding issues and considerations in the management of dyspepsia are discussed, providing an overview of current thinking and recommendations on patient management by primary care physicians and specialists.
- GORD, gastro-oesophageal reflux disease
- NSAIDs, non-steroidal anti-inflammatory drugs
- PPI, proton pump inhibitor
Conflict of interest: This symposium was sponsored by AstraZeneca, makers of omeprazole. The author of this paper has received sponsorship for travel and an honorarium from AstraZeneca.
NJ Talley has been a consultant and received research grants from TAP, Takeda, Ledede, Pharmacia, and Janssen.